Daniel E. Bauer

Daniel E. Bauer

Auto-generated profile, based on publicly available information

Daniel E. Bauer

Division of Hematology/Oncology, Boston Children’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
KCKendell Clement
Kendell Clement
HRHolly Rees
Holly Rees
MCMatthew C. Canver
Matthew C. Canver
JGJason M. Gehrke
Jason M. Gehrke
RFRick Farouni
Rick Farouni
LPLuca Pinello
Luca Pinello

16 September 2015 in Nature
Verified
Journal Article
Open access
PDF file
MCMatthew C. Canver
Matthew C. Canver
ESElenoe C. Smith
Elenoe C. Smith
FSFalak Sher
Falak Sher
LPLuca Pinello
Luca Pinello
NSNeville E. Sanjana
Neville E. Sanjana
DBDaniel E. Bauer
Daniel E. Bauer
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.

25 March 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YWYuxuan Wu
Yuxuan Wu
JZJing Zeng
Jing Zeng
BRBenjamin P. Roscoe
Benjamin P. Roscoe
PLPengpeng Liu
Pengpeng Liu
QYQiuming Yao
Qiuming Yao
DBDaniel E. Bauer
Daniel E. Bauer

12 July 2016 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
LPLuca Pinello
Luca Pinello
MCMatthew C Canver
Matthew C Canver
MHMegan D Hoban
Megan D Hoban
SOStuart H Orkin
Stuart H Orkin
DKDonald B Kohn
Donald B Kohn
GYGuo-Cheng Yuan
Guo-Cheng Yuan
To the Editor: Recent progress in genome editing technologies, in particular the CRISPR-Cas9 nuclease system, has provided new opportunities to investigate the biological functions of genomic sequences by targeted mutagenesis1, 2, 3, 4. Double-strand breaks (DSBs) arising from site-specific Cas9 cleavage can be resolved by non-homologous end joining (NHEJ) or homology-directed… Download references

16 March 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JZJing Zeng
Jing Zeng
YWYuxuan Wu
Yuxuan Wu
CRChunyan Ren
Chunyan Ren
JBJasmine Bonanno
Jasmine Bonanno
ASAnne H. Shen
Anne H. Shen
DBDaniel E. Bauer
Daniel E. Bauer

6 November 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
JMJean-Yves Métais
Jean-Yves Métais
PDPhillip A. Doerfler
Phillip A. Doerfler
TMThiyagaraj Mayuranathan
Thiyagaraj Mayuranathan
DBDaniel E. Bauer
Daniel E. Bauer
SFStephanie C. Fowler
Stephanie C. Fowler
MWMitchell J. Weiss
Mitchell J. Weiss
Key Points: Cas9 editing of the γ-globin gene promoters in hematopoietic stem cells (HSCs) increases red cell HbF by ≤40%. No deleterious effects on hematopoiesis or off-target mutations were detected 16 weeks after xenotransplantation of edited HSCs.